|
|
Volumn 126, Issue 2, 2013, Pages 385-386
|
|
Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
a
a
a
a
a
|
|
Author keywords
Hepatocellular carcinoma; Progression free survival; Sorafenib; Transarterial chemoembolization
|
|
Indexed keywords
ALPHA FETOPROTEIN;
PLACEBO;
SORAFENIB;
ARTICLE;
CANCER GROWTH;
CHEMOEMBOLIZATION;
COMPARATIVE STUDY;
COMPUTER ASSISTED TOMOGRAPHY;
CONTROLLED STUDY;
DEATH;
FOLLOW UP;
HISTOLOGY;
HUMAN;
LIVER CELL CARCINOMA;
LIVER FUNCTION;
LIVER INJURY;
MAJOR CLINICAL STUDY;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PROGRESSION FREE SURVIVAL;
PROSPECTIVE STUDY;
RANDOMIZED CONTROLLED TRIAL;
SIDE EFFECT;
SURVIVAL RATE;
TUMOR VOLUME;
AGED;
AGED, 80 AND OVER;
ANTINEOPLASTIC AGENTS;
CARCINOMA, HEPATOCELLULAR;
CHEMOEMBOLIZATION, THERAPEUTIC;
COMBINED MODALITY THERAPY;
DISEASE-FREE SURVIVAL;
HUMANS;
LIVER NEOPLASMS;
MIDDLE AGED;
NIACINAMIDE;
PHENYLUREA COMPOUNDS;
|
|
EID: 84872742913
PISSN: 03666999
EISSN: None
Source Type: Journal
DOI: 10.3760/cma.j.issn.0366-6999.20113067 Document Type: Article |
|
Times cited : (3)
|
|
References (3)
|
